Essential resources for NHS Wales e-Library users

13 October 2026

Extended Stability for Parenteral Drugs

This update contains corrections to Amphotericin (Liposomal), Etoposide, and Penicillin G Sodium.

13 October 2026

British National Formulary

This update contains 17 significant changes, 2 new monographs, 2 new preparations and 1 deleted monograph.

Significant Changes:

• Aminophylline: new dose equivalence and conversion statement.
• Avacopan: MHRA concludes review of avacopan following reassessment of benefit-risk balance [MHRA/CHM advice].
• Avacopan: new important safety information on updated requirements for liver monitoring and stopping rules to mitigate the risk of drug-induced liver injury and vanishing bile duct syndrome.
• Cardiovascular disease risk assessment and prevention: updated guidance on secondary prevention.
• Dexamethasone with hypromellose, neomycin and polymyxin B sulfate: name change to dexamethasone with neomycin and polymyxin B sulfate.
• Diabetes: updated guidance on driving.
• Heavy menstrual bleeding: updated guidance on management.
• Hypertension: updated guidance on non-drug treatment.
• Immune checkpoint inhibitors: updated important safety information on myocarditis-myositis-myasthenia gravis overlap syndrome (advice in avelumab, ipilimumab, nivolumab, pembrolizumab; see example in avelumab).
• Influenza vaccine (inactivated): update to guidance for egg allergy.
• Influenza vaccine (live): update to guidance for egg allergy and concomitant salicylate use.
• Influenza vaccine: updated guidance for 2026/27 influenza season.
• Primary biliary cholangitis: updated guidance on the use of seladelpar.
• Respiratory syncytial virus immunisation: updated guidance.
• Respiratory syncytial virus vaccine (Abrysvo®): new indication and dose for immunisation against respiratory syncytial virus [patients in a clinical risk group; as part of the national immunisation programme].
• Type 2 diabetes: updated guidance on management.
• Upadacitinib: new indication and dose for giant cell arteritis.

New Monographs:

• Brinsupri® [brensocatib].
• Tryngolza® [olezarsen].

New Preparations: Axhidrox® cream [glycopyrronium bromide]; Enebium® orodispersible tablet [rosuvastatin].

Deleted Monographs: Econazole nitrate.

13 October 2026

BNF for Children

This update contains 8 significant changes, 1 dose change, 1 new monograph, 2 new preparations and 1 deleted monograph.

Significant Changes:

• Aminophylline: new dose equivalence and conversion statement.
• Dexamethasone with hypromellose, neomycin and polymyxin B sulfate: name change to dexamethasone with neomycin and polymyxin B sulfate.
• Hypertension: updated guidance on non-drug treatment.
• Immune checkpoint inhibitors: updated important safety information on myocarditis-myositis-myasthenia gravis overlap syndrome (advice in ipilimumab, nivolumab, pembrolizumab; see example in ipilimumab).
• Influenza vaccine (inactivated): update to guidance for egg allergy.
• Influenza vaccine (live): update to guidance for egg allergy and concomitant salicylate use.
• Influenza vaccine: updated guidance for 2026/27 influenza season.
• Respiratory syncytial virus immunisation: updated guidance.

Dose Changes:

• House-dust mite extracts [update to age range].

New Monographs:

• Brinsupri® [brensocatib].

New Preparations: Enebium® orodispersible tablet [rosuvastatin]; Itulazax 12 SQ-Bet® [tree pollen extracts].

Deleted Monographs: Econazole nitrate.

13 October 2026

Stockley’s Herbal Medicines Interactions

USP-NF information has been updated. Minor updates to the interactions monographs of cranberry, grapefruit, pomegranate, and pomelo have also been made.

13 October 2026

Psychotropic Drug Directory

This update contains changes to 26 records.

New: 1.30 Delirium

Revisions: 1.13 Dementias, 1.21 Psychosis and schizophrenia

Minor updates: 1.0 Introduction; 1.2 Aggression; 1.4 Alcohol dependence and abuse; 1.5 Alcohol withdrawal syndrome; 1.6 Anxiety disorder; 1.9 Benzodiazepine dependence and withdrawal; 1.10 Bipolar mood disorder; 1.16 Insomnia; 1.19 Panic disorder; 1.23 Self-injurious behaviour; 1.25 Social anxiety disorder; 2.2.1.5 LAI and depot injections; 3.2 Cardiovascular (CV) disease; 3.7 Older adults; 3.8 Parkinson’s disease (PD); 5.1 Anxiety, agitation and nervousness; 5.4 Delirium (acute organic psychosis) dementia and confusion; 5.5. Depression; 5.15 Suicidal ideation; 6.3 Cardiac effects 6.4 Central adverse effects; 6.11 Weight gain; 7.0 Psychotropic drugs.

13 October 2026

Palliative Care Formulary

This update contains 6 revised monographs.

The following monographs have been fully revised: Lacosamide and oxcarbazepine (renamed from Oxcarbazepine); Phenobarbital.

The following monographs have been partially revised: Adjuvant analgesics; Anti-epileptics; Levetiracetam; Valproate.